Safety of sputum induction in moderate-to-severe smoking-related chronic obstructive pulmonary disease

COPD. 2006 Jun;3(2):89-93. doi: 10.1080/15412550600651339.

Abstract

Background: Investigation of the safety of sputum induction in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) has been limited.

Objective: to evaluate this issue in 100 patients with a mean FEV1 of 1.2 (0.4) L. After 200 microg inhaled salbutamol, sputum induction was performed with inhaled saline in increasing and tailored concentrations (0.9% to 5%) until an adequate sample of sputum was obtained or the FEV1 fell by >20%.

Main findings: Sputum induction was successful in 92% of occasions. The mean (SD) fall in FEV1 was 13.5 (8.6)%. Five patients had a fall >20% but all recovered to 10% of baseline after inhaled salbutamol. The magnitude of fall in FEV1 correlated weakly with salbutamol reversibility (r = 0.37, p < 0.001), baseline FEV1/VC (r = -0.32, p = 0.001) and baseline FEV1% predicted (r = -0.36, p = 0.003) but not with age, smoking history or post-Salbutamol FEV1. Principle

Conclusion: Sputum induction can be performed safely using a patient-tailored approach in patients with moderate-to-severe COPD, supporting its use in research and clinical practice.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Agonists / administration & dosage
  • Aged
  • Albuterol / administration & dosage
  • Area Under Curve
  • Cross-Sectional Studies
  • Female
  • Forced Expiratory Volume
  • Humans
  • Male
  • Middle Aged
  • Pulmonary Disease, Chronic Obstructive / etiology
  • Pulmonary Disease, Chronic Obstructive / physiopathology*
  • Respiratory Function Tests
  • Safety
  • Saline Solution, Hypertonic / administration & dosage*
  • Smoking / adverse effects*
  • Sputum / drug effects
  • Sputum / metabolism*
  • Statistics, Nonparametric

Substances

  • Adrenergic beta-Agonists
  • Saline Solution, Hypertonic
  • Albuterol